Pfizer is trading above its 50‑day moving average and has formed higher highs, while its >6% dividend yield and robust pipeline support fundamentals. The stock remains well‑positioned for further upside.

The Argus upgrade and a series of bullish headlines have lifted market sentiment, driving an 11% YTD rally. Investor enthusiasm fits the broader risk‑on trend in pharma.

Key risks include patent expirations and litigation exposure, but strong cash flow and a generous dividend cushion mitigate downside. Long‑term outlook stays positive with mRNA and oncology pipelines.

Technicals show RSI at 62, a bullish MACD crossover, and volume up ~30%, with price near $27.7, slightly above the average analyst target of $27.36. These signals suggest momentum toward the $35 high target.